Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Good
|
New words:
accelerated, accessory, accreted, accreting, accretion, AirTouch, Alere, ASC, assembled, assumption, Attorney, background, BBI, bio, Bluetooth, bundling, cap, category, Cellular, Chair, check, Clint, covenant, Cuttro, david, DCTM, debit, deductible, delinquent, Dirofilaria, disparate, division, DLL, DVM, efficient, Elanco, EmployerIdentification, EPOC, ESPP, Eyl, filer, forma, gather, inclusive, Indiana, infrastructure, intangible, IRS, knowledge, knowledgeable, Lage, Landen, lesser, Linkbase, LLLP, metabolite, moving, opportunistic, outflow, owed, PacTel, Page, par, PC, pm, POC, post, posted, preceding, prepaid, pro, redemption, referenced, relieved, Roth, Schema, Shawna, shell, shortened, sooner, spare, spouse, surcharge, sveen, tangible, Taxonomy, temperature, threshold, TM, transition, travel, trend, uncertain, understanding, unutilized, Verizon, voting, WiFi, workforce
Removed:
accutrend, acid, Additionally, adjunct, administer, application, Arkray, AVERT, bent, biotechnology, Brewing, brokerage, budgeted, burn, canceling, chain, clinically, collectibility, Controller, controversial, CPA, CRSP, daily, delaying, destroyed, diagnosed, discretionary, dropping, easy, endocrine, fatal, fatty, fewer, fish, flavor, flaxseed, formulation, frequency, FVRC, FVRCP, gland, GmbH, graph, hematocrit, hormone, Hypothyroid, hypothyroidism, immune, inflammatory, ingredientLevothyroxine, injectable, install, lab, left, lifetime, louise, mccormick, MIP, naturally, needle, obsolescence, occurring, oil, older, palatable, panleukopenia, parasiteDirofilaria, PCR, Pfizer, polymerase, proceeding, proven, reaction, replacement, respiratory, restructuring, row, seasonal, secreted, smallcap, Sodium, staffed, supplement, Supplementary, thyroid, timing, ULTRANASAL, underwent, untreated, unusually, unwilling
Filing tables
Filing exhibits
- 10-K Annual report
- 3 Bylaws
- 10.1 1997 Stock Incentive Plan
- 10.6 2003 Equity Incentive Plan
- 10.9 2013 Mip
- 10.10 2014 Mip
- 10.13 Employment Agreement Grieve
- 10.14 Restricted Stock Grant Grieve
- 10.15 Consulting Agreement (Founder Emeritus)
- 10.16 Employment Agreement Wilson
- 10.17 Restricted Stock Grant Wilson
- 10.23 Employment Agreement Eyl
- 10.55 Agreement Agri Laboratories
- 10.64 Agreement Intervet
- 21.1 Subsidiaries of the Company
- 23.1 Consent of Eks&h LLLP
- 31.1 Signature CEO
- 31.2 Signature CFO
- 32.1 Sigatures Ceo/cfo
- Download Excel data file
- View Excel data file
Related press release
HSKA similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Robert B. Grieve, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Heska Corporation on Form 10-K for the year ended December 31, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents in all material respects the financial condition and results of operations of Heska Corporation.
Date: March 31, 2014 | By: /s/ Robert B. Grieve |
Name: ROBERT B. GRIEVE | |
Title: Chairman of the Board and Chief | |
Executive Officer |
I, Jason A. Napolitano, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Heska Corporation on Form 10-K for the year ended December 31, 2013 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents in all material respects the financial condition and results of operations of Heska Corporation.
Date: March 31, 2014 | By: /s/ Jason A. Napolitano |
Name: JASON A. NAPOLITANO | |
Title: Executive Vice President and | |
Chief Financial Officer |
A signed original of this written statement required by Section 906 has been provided to Heska Corporation and will be retained by Heska Corporation and furnished to the Securities and Exchange Commission or its staff upon request.